Kinfo
Brillia Inc. logo

Brillia Inc.

BRIANYSEConsumer Cyclical·US · USD
$1.38
+0.08 (+5.99%)
Prices as of August 7, 2026 · market closed

Price

Key statistics

Valuation
Market cap34.50M USD
Enterprise value38.68M USD
Trailing P/E16.75
Forward P/E8.63
PEG ratio8.63
Price / sales0.70
Price / book2.89
Profitability
Gross margin0.00%
Operating margin-0.01%
Profit margin-0.03%
Return on assets0.67%
Return on equity-0.09%
Income (TTM)
Revenue48.99M USD
Gross profit6.96M USD
EBITDA4.65M USD
Net income-17.00K USD
Diluted EPS-$0.01
Rev. growth (YoY)-34.00%
Balance sheet
Total cash5.14M USD
Total debt1.54M USD
Debt / equity10.52
Current ratio2.23
Book value / share$0.48
Cash flow (TTM)
Operating cash flow261.00K USD
Levered free cash flow303.13K USD
Shares & price
Shares outstanding25.00M
Float20.28M
Held by institutions0.00%
Beta0.00
50-day MA$1.44
200-day MA$1.73
52-week high$4.95
52-week low$1.07
Dividends
Forward rate
$0.53
Yield
38.55%
Payout ratio
162.20%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-06-020.230.17−26.09%2025-10-170.660.69+4.55%2025-09-210.380.48+26.32%
About Brillia Inc.

Brillia Inc. is a thriving organization in the biotechnology sector, focusing on innovative healthcare solutions. The primary function of this company revolves around the development and commercialization of advanced therapeutic products aimed at treating diverse medical conditions. Known for their cutting-edge research in regenerative medicine and biologic therapies, Brillia Inc. significantly impacts the pharmaceutical and healthcare industries by introducing new methodologies that enhance patient care and treatment outcomes. Operating at the forefront of medical innovation, Brillia Inc. collaborates with research institutions and clinical experts to ensure the effectiveness and safety of its offerings. This collaborative approach enables the company to navigate regulatory landscapes efficiently and bring groundbreaking treatments to the market promptly. Brillia Inc.'s dedication to improving health outcomes through scientific discovery and its robust pipeline of therapeutic products make it a key player in the biotechnology industry. Its contributions not only advance patient therapy options but also support the broader goals of medical advancement and improved global health standards.

Sector
Consumer Cyclical
Industry
Apparel Retail
Employees
239
Headquarters
Singapore, Singapore

Frequently asked questions about Brillia Inc.